The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals
Open accessPublished version of a preprint
The DOI matches its Crossref record; 109 of the 111 references it cites were found in a registry or an index.
Abstract
This research uses mathematically derived visual logistics to interpret COVID-19 molecular and rapid antigen test (RAgT) performance, determine prevalence boundaries where risk exceeds expectations, and evaluate benefits of recursive testing along home, community, and emergency spatial care paths. Mathematica and open access software helped graph relationships, compare performance patterns, and perform recursive computations. Tiered sensitivity/specificity comprise: (T1) 90%/95%; (T2) 95%/97.5%; and (T3) 100%/≥99%, respectively. In emergency medicine, median RAgT performance peaks at 13.2% prevalence, then falls below T1, generating risky prevalence boundaries. RAgTs in pediatric ERs/EDs parallel this pattern with asymptomatic worse than symptomatic performance. In communities, RAgTs display large uncertainty with median prevalence boundary of 14.8% for 1/20 missed diagnoses, and at prevalence > 33.3–36.9% risk 10% false omissions for symptomatic subjects. Recursive testing improves home RAgT performance. Home molecular tests elevate performance above T1 but lack adequate validation. Widespread RAgT availability encourages self-testing. Asymptomatic RAgT and PCR-based saliva testing present the highest chance of missed diagnoses. Home testing twice, once just before mingling, and molecular-based self-testing, help avoid false omissions. Community and ER/ED RAgTs can identify contagiousness in low prevalence. Real-world trials of performance, cost-effectiveness, and public health impact could identify home molecular diagnostics as an optimal diagnostic portal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PB analysis indicates that, in order to avoid spreading disease with false negatives, RAgTs should achieve an initial sensitivity of at least 91.0 -91.4 % [76, 77] and Tier-3 speci fi city of ≥ 99 %.”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tiered sensitivity/speci fi city comprise: Tier-1) 90 %, 95 %; Tier-2) 95 %, 97.5 %; and Tier-3) 100 %, ≥ 99 %, respectively [74 -77].”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, H., Paulson, K. R., Pease, S. A., Watson, S., Comfort, H., Zheng, P., Aravkin, A. Y., Bisignano, C., Barber, R. M., Alam, T., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02796-3 · Cited by 2,069
Nagura-Ikeda, M., Imai, K., Tabata, S., Miyoshi, K., Murahara, N., Mizuno, T., Horiuchi, M., Kato, K., Imoto, Y., Iwata, M., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01438-20 · Cited by 397
SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
Vogels, C. B. F., Watkins, A. E., Harden, C. A., Brackney, D. E., Shafer, J., Wang, J., Caraballo, C., Kalinich, C. C., Ott, I. M., Fauver, J. R., et al. (2021) · Med · doi:10.1016/j.medj.2020.12.010 · Cited by 306
Van Vinh Chau, N., Lam, V. T., Dung, N. T., Yen, L. M., Minh, N. N. Q., Hung, L. M., Ngoc, N. M., Dung, N. T., Man, D. N. H., Nguyet, L. A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa711 · Cited by 243
Linares, M., Pérez-Tanoira, R., Carrero, A., Romanyk, J., Pérez-García, F., Gómez-Herruz, P., Arroyo, T., & Cuadros, J. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104659 · Cited by 236
Prince-Guerra, J. L., Almendares, O., Nolen, L. D., Gunn, J. K. L., Dale, A. P., Buono, S. A., Deutsch-Feldman, M., Suppiah, S., Hao, L., Zeng, Y., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7003e3 · Cited by 214
Cerutti, F., Burdino, E., Milia, M. G., Allice, T., Gregori, G., Bruzzone, B., & Ghisetti, V. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104654 · Cited by 197
Gremmels, H., Winkel, B. M. F., Schuurman, R., Rosingh, A., Rigter, N. A. M., Rodriguez, O., Ubijaan, J., Wensing, A. M. J., Bonten, M. J. M., & Hofstra, L. M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100677 · Cited by 176
Pilarowski, G., Lebel, P., Sunshine, S., Liu, J., Crawford, E., Marquez, C., Rubio, L., Chamie, G., Martinez, J., Peng, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa802 · Cited by 164
Pollock, N. R., Jacobs, J. R., Tran, K., Cranston, A. E., Smith, S., Kane, C. O., Roady, T. J., Moran, A., Scarry, A., Carroll, M., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00083-21 · Cited by 146
Research works printed but not linked: 3
- 4. Kost G.J., Ferguson W.J., Kost L.E. Principles of point of care culture, the spatial care path, and enabling community and global resilience. J. Int. Fed. Clin. Chem. Lab. Med. 2014;25:4–23.
- 5. Kost G.J., Ferguson W.J., Truong A.-T., Prom D., Hoe J., Banpavichit A., Kongpila S. The Ebola Spatial Care PathTM: Point-of-care lessons learned for stopping outbreaks. Clin. Lab. Int. 2015;39:6–14.
- 112. Eng M., Zadran A., Kost G.J. Covid-19 risk avoidance and management in limited-resource countries—Point-of-care strategies for Cambodia. Omnia Digital Health. June–July, 2021. [(accessed on 26 April 2022)]. pp. 112–115. Available online: https://secure.viewer.zmags.com/publication/44e87ae6?page=115&nocache=1625391874149&fbclid=IwAR2gIObRf6ThX15vlBpqMRYSC83hiZysJ8uMxEae7Em16bhOrnfEJTgNWuo#/44e87ae6/115.
Cited by
Point-of-care testing: state-of-the art and perspectives
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0675 · Cited by 119
Self-citationBaldeh, M., Bawa, F. K., Bawah, F. U., Chamai, M., Dzabeng, F., Jebreel, W. M. A., Kabuya, J.-B. B., Dele-Olowu, S. K. M., Odoyo, E., Robinson, D. R., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2277368 · Cited by 31
“…specific POCTs need to be in order to be useful, in which disease prevalence is a major consideration, but selection of molecular POCTs over other forms of rapid diagnostic test is often justified if high sensitivity and specificity are required for the situation in which they will be used [16,17].”
BackgroundOptimizing Public Health Preparedness for Highly Infectious Diseases in Central Vietnam
Zadran, A., Ho, A. V. D., Zadran, L., Curiel, I. J. V., Pham, T.-T., Thuan, D. T. B., & Kost, G. J. (2022) · Diagnostics · doi:10.3390/diagnostics12092047 · Cited by 11
“Point-of-care testing programs can be designed and implemented in rural and remote areas to educate and train healthcare staff on the use of RAgTs for infectious diseases [68].”
BackgroundSelf-citationKost, G. J., Füzéry, A. K., Caratao, L. K. R., Tinsay, S., Zadran, A., & Ybañez, A. P. (2023) · International Journal of Health Geographics · doi:10.1186/s12942-023-00359-y · Cited by 8
“A diagnostic portal is the geographic entry point from home to hospital where the patient self-tests or first seeks, obtains, or is administered diagnostic testing to rule in or rule out a medical condition and then expeditiously receives care [8].”
BackgroundInfluentialSelf-citationWeb-accessible critical limits and critical values for urgent clinician notification
Kost, G. J., Dohner, J., Liu, J., Ramos, D., Haider, N., & Thalladi, V. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0117 · Cited by 7
“%) likely bene fi t from enhanced awareness, accelerated infection control, and mitigated contagion [25, 26].”
Self-citationKost, G. J. (2023) · Diagnostics · doi:10.3390/diagnostics13203223 · Cited by 5
“[19].”
BackgroundSelf-citationVisualization of Critical Limits and Critical Values Facilitates Interpretation
Shah, A., Dohner, J., Cheng, K., Garcia, M., & Kost, G. J. (2025) · Diagnostics · doi:10.3390/diagnostics15050604 · Cited by 4
“This is a significant omission, as urgent notification of this pandemic threat can enhance awareness, accelerate infection control, and mitigate contagion [50,51].”
Self-citationKost, G. J., Eng, M., & Zadran, A. (2024) · JMIR Public Health and Surveillance · doi:10.2196/47416 · Cited by 1
“Home, community, and emergency testing [10,40], [95].”
BackgroundMethodInfluentialSelf-citationFüzéry, A. K., Kost, G. J., & Tran, N. K. (2022) · Wiley eBooks · doi:10.1002/9780470027318.a9797 · Cited by 1
Self-citationKost, G. J., Füzéry, A. K., Caratao, L. K. R., Tinsay, S., Zadran, A., & Ybañez, A. P. (2024) · Figshare · doi:10.6084/m9.figshare.26656849
Self-citationKost, G. J., Füzéry, A. K., Caratao, L. K. R., Tinsay, S., Zadran, A., & Ybañez, A. P. (2024) · Figshare · doi:10.6084/m9.figshare.26656852
Self-citation
Metadata
- Authors
- Kost, G. J.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Kost, Gerald J.
- ORCID
- Kost, Gerald J.
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2022-05-12
- Volume
- 12
- Issue
- 5
- Pages
- 1216
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC9140623
- OpenAlex
- W4280647568
- Cited by
- 13
- References
- 111
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 3 · 2022: 4
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Point-of-Care Testing Center for Teaching and Research (POCT•CTR)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 pandemic, rapid antigen test, molecular diagnosis, diagnostic performance, prevalence threshold, home testing, self-testing, emergency department testing, community-based testing, missed diagnosis, asymptomatic infection, saliva testing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.